1 of 65

Drug Use Trends and Treatment Implications for Pregnant and Birthing People: National and State Data

February, 2024

Sarah E. Wakeman, MD

Senior Medical Director for Substance Use Disorder, MGB

Medical Director, Mass General Hospital Program for Substance Use & Addiction Services

Associate Professor of Medicine, Harvard Medical School

1

2 of 65

Objectives

  1. Describe the epidemiology of substance use trends
  2. Define the full spectrum of substance use
  3. Review screening and diagnosis for SUD in pregnancy
  4. Delineate components of effective treatment for pregnant and birthing people

Office of Continuing Professional Development | Confidential—do not copy or distribute

2

3 of 65

Epidemiology

3

4 of 65

Rising rates of drug-related overdose

4

5 of 65

US leads the globe in overdose deaths

5

6 of 65

Nationally, overdose deaths are rising & disparities worsening�

In just one year, overdose death rates increased 44% for Black people and 39% for American Indian and Alaska Native (AI/AN) people

6

7 of 65

Overdose deaths in Arizona

7

8 of 65

44.5% increase in overdose death rate among young people

Rossen LM, Resendez A, Behdin A, Louis MS. Trends and disparities in deaths among young persons in the US during the COVID-19 pandemic. Ann Epidemiol. 2024 Feb 2;91:37-43. doi: 10.1016/j.annepidem.2024.01.009. Epub ahead of print. PMID: 38309641.

8

9 of 65

Overdose contributing to increase in non-obstetric maternal deaths across the US

  • From 2000-2019, overdose accounted for 9.4% of all maternal deaths in the US

  • Overdose accounted for 27.3% of all non-obstetric maternal deaths in the US

  • In Michigan from 2007-2015, 24.1% of pregnancy associated not related deaths were due to opioid use disorder

Huang RS, Spence AR, Abenhaim HA. Non-Obstetric Maternal Mortality Trends by Race in the United States. Matern Child Health J. 2023 Dec 26. doi: 10.1007/s10995-023-03862-7. Epub ahead of print. PMID: 38147278.

Putra M, Roy M, Nienhouse V, Patek K, Sokol R. Comparing Antepartum and Postpartum Opioid-Related Maternal Deaths in the State of Michigan From 2007 to 2015. Cureus. 2023 Nov 12;15(11):e48690. doi: 10.7759/cureus.48690. PMID: 38090407; PMCID: PMC10715364.

9

10 of 65

Overdose Risk Increase in Postpartum Period

Schiff et al. Obstet Gynecol. 2018 Aug;132(2):466-474

10

11 of 65

Ongoing Death Toll Due to Unregulated Fentanyl

11

12 of 65

Co-involved substance in IMF-related overdose deaths

12

13 of 65

Non-fatal overdoses in Arizona

13

14 of 65

Rising alcohol related mortality: 26% higher since COVID

14

15 of 65

Alcohol use in pregnancy

  • In 2022, 11% of pregnant people reported past month alcohol use
  • 5.3% reported past month binge alcohol use

15

16 of 65

Epidemiology of Alcohol Use Disorder

AUD 12-month & lifetime prevalence 13.9% & 29.1%

Prevalence highest:

    • men (17.6% & 36.0%)
    • white individuals (14.0% & 32.6%)
    • Native/tribal individuals (19.2% & 43.4%)

Grant et al. JAMA Psychiatry. 2015;72(8):757–766

16

17 of 65

Disparities in Alcohol Use Among Women: Intersectional Lens

17

18 of 65

High Prevalence of Unhealthy Substance Use in General Medical Settings

Wakeman SE, Herman G, Wilens TE, Regan S. Subst Abus. 2020;41(3):331-339.

18

19 of 65

Epidemiology of SUD

NSDUH 2022 https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022-nsduh-nnr.pdf

19

20 of 65

20

21 of 65

21

22 of 65

Proportion of delivery hospitalizations with SUD rising

Logue TC, Wen T, Friedman AM. Demographic trends associated with substance use disorder and risk for adverse obstetric outcomes with cannabis and opioid use disorders. J Matern Fetal Neonatal Med. 2022 Dec;35(26):2128658.

22

23 of 65

OUD clinically documented in Pregnancy

  • Among Medicaid enrollees, 2.7 % (65,092 individuals) had a documented OUD during pregnancy
  • In Arizona, 2.5%

23

24 of 65

SUD Treatment Gaps

24

25 of 65

MOUD Treatment gaps

25

26 of 65

MOUD in pregnancy

  • Overall, among Medicaid enrollees the MOUD treatment rate in pregnancy is 54%
  • Ranges from a low of 19% in Kansas to a high of 79% in Maine
  • In Arizona, rate is on par with national average (53%)
  • Racial disparities exist with 31% of Black pregnant people receiving treatment compared to 57% of White pregnant people

https://www.kff.org/medicaid/issue-brief/opioid-use-disorder-and-treatment-among-pregnant-and-postpartum-medicaid-enrollees/#:~:text=Prior%20studies%20indicate%20that%20only,any%20medication%20to%20treat%20OUD.

26

27 of 65

What is and what isn’t SUD?

27

28 of 65

What is and what isn’t SUD?

The defining feature is compulsively using a substance despite negative consequences

Defined as a problematic pattern of alcohol or drug use leading to clinically significant impairment or distress within a 1-year period

Based on meeting at least 2 of 11 criteria from DSM-5

Criteria assess for loss of control of use, compulsive use, use despite consequences, and craving

28

29 of 65

Spectrum of Alcohol Use

Saitz R. New Engl J Med 2005;352:596

29

30 of 65

Spectrum of all substance use

30

31 of 65

Screening and Brief Intervention for Unhealthy Substance Use

31

32 of 65

Addiction Medicine Basics: What Does a Non-Specialist Need to Know?

How to screen for and diagnose unhealthy substance use and SUD

How to address a positive screen

What effective treatment for SUD looks like

How to care for mild to moderate SUD

How to reduce negative consequences of ongoing use

32

33 of 65

Screening and Diagnosis

  • Just like other diseases, there are sensitive screening tools & specific diagnostic tools
  • Single Item Screening Question (SISQ)
  • AUDIT-C
  • DAST-10
  • Effective for screening in general medical settings and among pregnant people, albeit less data
  • Screening tools unique to pregnancy: Substance Use Risk Profile-Pregnancy (SURP-P) and 4Ps Plus

33

34 of 65

What now? Responses to a moderate risk screen result

Brief intervention: 5-15 minutes

    • Feedback
    • Advice
    • Goal setting

Motivational interviewing (MI):

    • client-centered counseling to elicit behavior change by helping explore & resolve ambivalence

“Spirit” of Motivational Interviewing:

    • collaboration (partnership),
    • evocation (listening and eliciting)
    • autonomy (ability to choose)

34

35 of 65

Brief Negotiated Interview

Provides structured format for using MI skills in the context of clinical care

Build Rapport

Explore pros and cons

Ask for permission to give feedback

Assess readiness to change

(BNI-ART Institute, BU School of Public Health)�

35

36 of 65

Negotiating an Action Plan

Identify health related goal– pregnancy highly motivating moment for many

Seek ideas from patient

Patient strengths and supports

Collaborate with patient to develop plan

Summarize and write plan with permission

    • Small, doable steps
    • Patient commitment

36

37 of 65

Beware The Righting Reflex�

Desire to set things “right” or “fix” the patient

Most people dislike being told what to do

37

38 of 65

Steps For Successful BI

R - Resist the righting reflex

U - Understand the person, develop empathy (use open-ended questions)

LListen! (use reflections to convey understanding and empathy)

E – Build self-Efficacy (convey support and confidence in person’s ability to make changes)

Goal is to evoke the patient’s own reasons for change

38

39 of 65

Open-Ended Questions, Affirmations, Reflections

    • “Have you ever tried to cut back on your drinking in the past?”

Open-Ended Questions

    • “Why did you decide to make that change?”

Elaborate

    • “It takes a lot of strength to make those changes.”

Affirm

    • “It sounds like you are ready to stop drinking.”

Reflect

39

40 of 65

Ambivalence is Normal

I don’t want to change

I want to change

40

41 of 65

Recognizing Change Talk

I know I should stop using fentanyl but I don’t have time to go to treatment. When I took buprenorphine it made me sick, I must be allergic. I didn’t like AA meetings, everyone just complains. I can do this on my own.

41

42 of 65

Recognizing Change Talk

I know I should stop using fentanyl but I don’t have time to go to treatment. When I took buprenorphine it made me sick, I must be allergic. I didn’t like AA meetings, everyone just complains. I can do this on my own.

42

43 of 65

Strengthening Change Talk

I know I should stop using fentanyl but I don’t have time to go to treatment. When I took buprenorphine it made me sick, I must be allergic. I didn’t like AA meetings, everyone just complains. I can do this on my own.

You are determined to stop using fentanyl. What made you decide to try medication treatment and go to AA meetings in the past?

43

44 of 65

Strengthening Change Talk

    • “I don’t drink anymore than my friends do. Sure I sometimes miss work but it isn’t a problem.”
    • “You are worried about how alcohol is affecting your work”

Selective responding

    • “You stayed sober for two years in the past on buprenorphine, how were you able to do that?”

Looking back at past successes

    • “Is there anything you would experience in the future that would make you more concerned about your alcohol use?”

Looking ahead to future goals

44

45 of 65

Change Talk Bouquet

You’re worried that your opioid use could be harmful to your pregnancy, and your partner has mentioned that they are concerned. You have started thinking about making changes and you are confident you can do so. In the past buprenorphine has helped you stop using.

  • KEY QUESTION: Where should we go from here?

45

46 of 65

46

47 of 65

Diagnosis and Treatment

47

48 of 65

Making a diagnosis of SUD:�A problematic pattern of use leading to clinically significant impairment, meeting at least two of the following criteria in 12 month period (2-3 mild, 4-5 moderate, 6+ severe)

Substance taken in larger amounts or over a longer period of time than was intended.

There is a persistent desire or unsuccessful efforts to cut down or control substance use.

A great deal of time spent in activities to obtain, use, or recover from substance.

Craving, or a strong desire or urge to use substance.

Recurrent substance use resulting in a failure to fulfill major role obligations.

Continued substance use despite having persistent or recurrent social or interpersonal problems.

Important social, occupational, or recreational activities are given up or reduced.

Recurrent substance use in situations in which it is physically hazardous.

Continued substance use despite knowledge of having a persistent or recurrent physical or psychological problem that’s

likely to have been caused or exacerbated by the substance.

Tolerance*

Withdrawal*

* Tolerance and withdrawal insufficient to make diagnosis if due to prescribed medication

48

49 of 65

Initiating effective treatment

MEDICATION

PSYCHOSOCIAL INTERVENTIONS

RECOVERY SUPPORTS

HARM REDUCTION

49

50 of 65

Pharmacotherapy: FDA approved (and non-approved) medications for AUD, OUD, TUD, no FDA-approved medications for stimUD, some with limited benefit in trials�

Alcohol use disorder: naltrexone, acamprosate, disulfiram (all category C)

Opioid use disorder: methadone, buprenorphine (both considered first line in pregnancy)

Tobacco use disorder: varenicline, bupropion, NRT

50

51 of 65

Most treated patients with OUD achieve remission

CONTINUING MEDICAL EDUCATION DEPARTMENT OF MEDICINE

51

52 of 65

SBIRT to STIR: screen, treatment initiation, refer if needed

Identify patients through screening or acute presentation

Make a diagnosis

Initiate treatment without delay

Retain patients in treatment

52

53 of 65

What are the goals of treatment? Patient-centered, patient-driven care

  • First and foremost, for the patient’s life and health to improve
  • It doesn’t matter why anyone thinks someone should make changes to their substance use, it only matter that the affected individual thinks their life will get better if they do
  • Giving a menu of options, based on science
  • Rooted in respect for autonomy, enhancing self-efficacy, holding hope
  • Celebrating progress, not perfection

53

54 of 65

Essential components of care are just like those for other medical conditions

  • Why aren’t all providers & health systems doing this?

  • Barriers often cited (time, resources, multi-morbidity) exist for other conditions too

  • We don’t talk enough about joy & satisfaction of this work!�

Identify

Discuss diagnosis

Treat

Refer (when needed)

54

55 of 65

Unique issues in perinatal SUD management

55

56 of 65

Caring for Pregnant & Parenting People with SUD

Pregnant people are also human beings– deserve same standard of care

During pregnancy, methadone or buprenorphine standard of care

Lactation support!

56

57 of 65

Racial disproportionality has long existed in perinatal toxicology testing

In a national cohort study of 26,366 births from 2014 to 2020, clinicians were more likely to order drug tests for Black newborns (7.3%) compared with White newborns (1.9%) and other racial and ethnic groups

Schoneich S, Plegue M, Waidley V, et al. Incidence of Newborn Drug Testing and Variations by Birthing Parent Race and Ethnicity Before and After Recreational Cannabis Legalization. JAMA Netw Open. 2023;6(3):e232058.

57

58 of 65

In 2019, >5% of Black infants in the US were subjected to child welfare investigation from medical professional report

Edwards F, Roberts SCM, Kenny KS, Raz M, Lichtenstein M, Terplan M. Medical Professional Reports and Child Welfare System Infant Investigations: An Analysis of National Child Abuse and Neglect Data System Data. Health Equity. 2023 Sep 29;7(1):653-662. doi: 10.1089/heq.2023.0136. PMID: 37786528; PMCID: PMC10541941.

58

59 of 65

Impact of Custody Loss

Substance use is a main reason for child welfare involvement

Economically disadvantaged Black communities experience intense social surveillance and more likely to be reported to child welfare authorities

Research on effect of parent-child separation on the child has demonstrated negative impact, less known about impact on the parent

Significant psychological toll, “emotions of guilt, bitterness, anger, feelings of failure as a parent, and helplessness”

Harp KL, Oser CB. Child Abuse Negl. 2018 Mar; 77: 1–12.

59

60 of 65

Impact of custody loss

Harp KL, Oser CB. Child Abuse Negl. 2018 Mar; 77: 1–12.

Longitudinal analysis of 339 Black women analyzed the effects of custody loss on subsequent drug use

Losing official custody increased drug use by a factor of 4.14

Unofficial custody loss increased drug use by a factor of 1.72

60

61 of 65

Call to action from the Biden-Harris Administration: All pregnant people with SUD should be prioritized to receive evidence-based treatment & support

Five key values from federal report:

1. Having SUD in pregnancy is not, by itself, child abuse or neglect.

2. Criminalizing SUD in pregnancy is ineffective and harmful as it prevents pregnant women with SUD from seeking and receiving the help they need.

3. Everyone has the right to effective treatment, and denying such care on the basis of sex or disability is a violation of civil rights.

4. Pregnant women using substances or having SUD, should be encouraged to access support and care systems, and barriers to access should be addressed, mitigated, and eliminated where possible.

5. Improving coordination of public health, criminal justice systems, treatment and early childhood systems can optimize outcomes and reduce disparities.

61

62 of 65

“ASAM strongly supports reforms to reverse the punitive approach taken to substance use and SUD during and after pregnancy and respond to the shared interests of the parent-newborn dyad by providing ethical, equitable, and accessible, evidence-based care.”

62

63 of 65

An approach to supporting equitable perinatal SUD care

Universal screening to identify pregnant people in need of support

Thoughtful and judicious use of toxicology testing, with written consent

Immediate access to person-centered treatment and low barrier initiation of pharmacotherapy

Rooming in and dyadic care during delivery hospitalization

Trauma-informed, equity-informed care models and policies

Disentangling substance exposure from protective concerns

63

64 of 65

Thank you!

@DrSarahWakeman

64

65 of 65

65